Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.

@article{Fabbri2009RoflumilastIM,
  title={Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.},
  author={Leonardo M Fabbri and Peter M. A. Calverley and Jos{\'e} Luis Izquierdo-Alonso and Daniela S. Bundschuh and Manja Brose and Fernando J Martinez and Klaus Friedrich Rabe},
  journal={Lancet},
  year={2009},
  volume={374 9691},
  pages={695-703}
}
BACKGROUND Patients with chronic obstructive pulmonary disease (COPD) have few options for treatment. The efficacy and safety of the phosphodiesterase-4 inhibitor roflumilast have been investigated in studies of patients with moderate-to-severe COPD, but not in those concomitantly treated with longacting inhaled bronchodilators. The effect of roflumilast on lung function in patients with COPD that is moderate to severe who are already being treated with salmeterol or tiotropium was investigated… CONTINUE READING
Highly Influential
This paper has highly influenced 29 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
198 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 198 extracted citations

Similar Papers

Loading similar papers…